Volume 6, Issue 4 (Journal of Clinical and Basic Research (JCBR) 2022)
jcbr 2022, 6(4): 19-22 |
Back to browse issues page
Ethics code: Registered No ECR/84/Inst/OR/2013 issued under Rule 122DD of the Drugs and Cosmetics Rules 1945) SCB
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nayak S, Mohapatra D. Irisin, a new envoy in newly diagnosed type 2 diabetes mellitus – A plausible association with insulin resistance. jcbr 2022; 6 (4) :19-22
URL: http://jcbr.goums.ac.ir/article-1-383-en.html
URL: http://jcbr.goums.ac.ir/article-1-383-en.html
1- Saffalya Nayak - Biochemistry SCB MCH - SCB MCH, Cuttack , nayaksaffalya@gmail.com
2- Debjyoti Mohapatra - Community Medicine SJMCH - SJ Medical College, Puri
2- Debjyoti Mohapatra - Community Medicine SJMCH - SJ Medical College, Puri
Abstract: (592 Views)
Background: Insulin resistance plays a significant role in the pathogenesis of type 2 diabetes mellitus (T2DM). Irisin, an adipo-myokine, is found to increase insulin sensitivity by adaptive thermogenesis. Various studies have found that endocrine and exocrine functions of the pancreas are affected in T2DM. This case-control study with 180 participants aimed to find any association of serum irisin with insulin resistance and pancreatic profile in newly diagnosed T2DM.
Methods: Fasting blood sugar (FBS) and pancreatic profile were measured by Auto Analyzer, serum insulin by chemiluminescence assay, serum irisin by Enzyme-Linked Immunoassay (ELISA) kit, and insulin resistance by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
Results: Significantly lower irisin levels were observed in T2DM patients compared to healthy individuals (p =0.001*). A positive correlation was found between serum irisin and insulin resistance in T2DM patients, whereas a negative correlation was found in healthy controls. In some cases, serum amylase and lipase positively correlated with irisin, whereas a negative association was observed in controls.
Conclusion: This study concludes a protective role for irisin in combating insulin resistance and improving pancreatic function in T2DM, but more extensive studies are required to prove it.
Methods: Fasting blood sugar (FBS) and pancreatic profile were measured by Auto Analyzer, serum insulin by chemiluminescence assay, serum irisin by Enzyme-Linked Immunoassay (ELISA) kit, and insulin resistance by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
Results: Significantly lower irisin levels were observed in T2DM patients compared to healthy individuals (p =0.001*). A positive correlation was found between serum irisin and insulin resistance in T2DM patients, whereas a negative correlation was found in healthy controls. In some cases, serum amylase and lipase positively correlated with irisin, whereas a negative association was observed in controls.
Conclusion: This study concludes a protective role for irisin in combating insulin resistance and improving pancreatic function in T2DM, but more extensive studies are required to prove it.
Keywords: Diabetes Mellitus, Type 2, Insulin resistance, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Pancreatic profile
Article Type: Research |
Subject:
Biochemistry
References
1. Bommer C, Sagalova V, Hessemann E, Jennifer M, Atun R, Barnighausen T, et al; Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. Diabetes Care. 2018;41(5):963-70. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: The Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6(12):e1352-62. [View at Publisher] [DOI] [Google scholar] [PubMed]
3. Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97-105. [View at Publisher] [DOI] [PMID] [PMCID] [Google scholar]
4. Rodriguez A, Becerril S, Ezquerro S, Mendez-Gimenez L, Fruhbeck G. Crosstalk between adipokines and myokines in fat browning. Acta Physiol. 2017; 219(2):362-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature. 2012;481(7382):463-8. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
6. Norheim F, Langleite TM, Hjorth M, Holen T, Kielland A, Stadheim HK. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014;281(3):739‐49. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Alencar, Jaqueline, Luna, Francisco, Coelho, Matheus, et al; Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review. International Archives of Medicine. 2017;10(171). [View at Publisher] [DOI] [Google scholar]
8. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE; Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98(12):4899-907. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
9. World Health Organization. Classification of diabetes mellitus. World Health Organization; Geneva:2019. License: CC BY-NC-SA 3.0 IGO. [View at Publisher] [Google scholar]
10. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assassment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985;28(7):412-19. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. World Health organization. Guide to physical measurements; WHO STEPS surveillance manual:2017. [View at Publisher]
12. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK. Serum irisin levels in new- onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):96‐101. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud A, Mousa M, Khalifa A. Circulating serum Irisin Levels in Obesity and Type 2 Diabetes Mellitus. IUBMB Life. 2016;68(7):544-56. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y. Irisin Stimulates Browning of White Adipocytes through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signalling. Diabetes. 2014;63(2):514-25. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Shi X, Lin M, Liu C, Xiao F, Liu Y, Huang P, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults. BMC Endocr Disord. 2016;16:44. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
16. Huth C, Dubois MJ, Marette A, Tremblay A, Weisnagel SJ, Lacaille M, et al. Irisin is more strongly predicted by muscle oxidative potential than adiposity in non-diabetic men. J Physiol Biochem. 2015;71(3):559-68. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin Is Expressed and Produced by Human Muscle and Adipose Tissue in Association with Obesity and Insulin Resistance. J Clin Endocrinol Metab. 2013;98(4):E769-78. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM, et al; Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis. Metabolism. 2016;65(6):825-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Nakajima, Kei. Low serum amylase and obesity, diabetes and metabolic syndrome: A novel interpretation. World J Diabetes. 2016;7(6):112-21. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
20. Srihardyastutie A, Soeatmadji DW, Fatchiyah, Aulanni'am. Relation of Elevated Serum Lipase to Indonesian Type 2 Diabetes Mellitus Progression. Biomedical Research. 2015;26(2):293-98. [View at Publisher] [Google Scholar]
21. Snehankar K, Rumi D, Risha G, Kailash B. Serum amylase and lipase activities in newly diagnosed patients with type 2 diabetes mellitus. International Journal of Advanced Research (IJAR). 2016;4(7):1476-83. [View at Publisher] [DOI] [Google Scholar]
22. Panati K, Suneetha Y, Narala VR. Irisin/FNDC5 - An updated review. Eur Rev Med Pharmacol Sci. 2016;20(4):689-97. [View at Publisher] [DOI] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).